Get to know our clinical trials
Basket, Phase 2, multicenter, open-label, multicenter study of MK-7684A, a coformulation of vibostolimab (MK-7684) with pembrolizumab (MK- 3475), with or without other antineoplastic therapies, in participants with selected solid tumors (KEYVIBE-005) "Immunotherapy"
THE AIM OF THIS TRIAL IS TO EVALUATE MK-7684A IN PEOPLE WITH CERTAIN TYPES OF SOLID TUMORS.
Technical Summary
- BASKET, PHASE 2, MULTICENTER, OPEN-LABEL, MULTICENTER STUDY OF MK-7684A, A COFORMULATION OF VIBOSTOLIMAB (MK-7684) WITH PEMBROLIZUMAB (MK- 3475), WITH OR WITHOUT OTHER ANTINEOPLASTIC THERAPIES, IN PARTICIPANTS WITH SELECTED SOLID TUMORS (KEYVIBE-005) "IMMUNOTHERAPY"
- Code EudraCT: 2021-001009-56
- Protocol number: MK-7684A-005
- Promoter: Merck Sharp & Dohme, S.A.
- Molecule/Drug: Pembrolizumab/Vibostolimab Co-Formulation
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.